JMP keeps ViroPharma at market outperform

ViroPharma Inc. was reiterated by JMP Securities analyst Adam Cutler at market outperform. ViroPharma reported fourth-quarter 2005 financial results. Sales of $40.3 million beat JMP's estimate of $37.1 million. Fourth-quarter earnings per share of $1.17 ($0.41 excluding a one-time tax benefit) were higher than the analyst's estimate of $0.31 and the Street consensus of $0.28. ViroPharma issued 2006 guidance of $160-$170 million for Vancocin sales. Shares of the Exton, Pa., biopharmaceutical company were down $1.95, or 9.15%, at $19.35 on volume of 5,263,802 shares versus the three-month running average of 1,569,060 shares. (Nasdaq: VPHM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.